(Q38113098)

29 August 2017

Effects of dapagliflozin on cardiovascular risk factors (English)

1 reference

29 August 2017

1 reference

Agata Ptaszynska

1

1 reference

29 August 2017

Elise Hardy

2

1 reference

29 August 2017

Eva Johnsson

3

1 reference

29 August 2017

Shamik Parikh

4

1 reference

29 August 2017

James List

5

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 May 2013

1 reference

29 August 2017

Postgraduate Medicine

1 reference

29 August 2017

125

1 reference

29 August 2017

3

1 reference

29 August 2017

181-189

1 reference

Diabetes and cardiovascular disease. The Framingham study

29 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Rosiglitazone: what went wrong?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Metabolic syndrome pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the Ameri

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Microalbuminuria and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

The association between serum uric acid level and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Cardiovascular events and intensity of treatment in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

The cardiovascular effects of erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Polycythemia vera: myths, mechanisms, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

New agents that stimulate erythropoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

2007 ESH‐ESC Guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2667

21 January 2018

Identifiers

DOI

10.3810/PGM.2013.05.2667

1 reference

29 August 2017

1 reference